JNJ says it’s looking to strengthen its position as a solutions provider for the world’s top cause of death—cardiovascular disease.
Johnson & Johnson has announced that it is acquiring the Danvers, Massachusetts-based medical technology company Abiomed for $16.6 billion. Here’s what you need to know:
Read Full Story